Rezultati - Suzanne Trudel

Refine Results
  1. 1
    Antibodies and bispecifics for multiple myeloma: effective effector therapy

    Antibodies and bispecifics for multiple myeloma: effective effector therapy od Christopher Cipkar, Christine Chen, Suzanne Trudel

    Izdano 2022
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Actin assembly in electropermeabilized neutrophils: role of intracellular calcium.

    Actin assembly in electropermeabilized neutrophils: role of intracellular calcium. od Gregory P. Downey, C K Chan, Suzanne Trudel, Sergio Grinstein

    Izdano 1990
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

    Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma od Hong Chang, A. Keith Stewart, Qi Xiao, Zhihua Li, Qi Long Yi, Suzanne Trudel

    Izdano 2005
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

    Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma od Suzanne Trudel, Zhihua Li, Jennifer Rauw, Rodger E. Tiedemann, Xiao‐Yan Wen, A. Keith Stewart

    Izdano 2007
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

    Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma od Suzanne Trudel, Scott Ely, Yildiz Farooqi, Maurizio Affer, Davide F. Robbiani, Marta Chesi, P. Leif Bergsagel

    Izdano 2004
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance

    Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance od Wilfrid Jaksic, Suzanne Trudel, Hong Chang, Young Trieu, Qi Xi, Joseph Mıkhael, Donna Reece, Christine Chen, A. Keith Stewart

    Izdano 2005
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

    CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma od Suzanne Trudel, Zhihua Li, Ellen Wei, Marion Wiesmann, Hong Chang, Christine Chen, Donna Reece, Carla Heise, A. Keith Stewart

    Izdano 2004
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

    Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma od Donna Reece, Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mıkhael, Mariela Pantoja, Wei Xu, A. Keith Stewart

    Izdano 2008
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

    Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival od Víctor H. Jiménez‐Zepeda, Joseph Mıkhael, Andrew Winter, Norman Franke, Esther Masih‐Khan, Suzanne Trudel, Christine Chen, Vishal Kukreti, Donna Reece

    Izdano 2011
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

    Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma od James W. Clendening, Aleksandra A. Pandyra, Zhihua Li, Paul C. Boutros, Աննա Մարտիրոսյան, Richard Lehner, Igor Jurišica, Suzanne Trudel, Linda Z. Penn

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development od Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial

    Izdano 2025
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma

    D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma od Alina S. Gerrie, Joseph Mıkhael, Lu Cheng, Haiyan Jiang, Vishal Kukreti, Tony Panzarella, Donna Reece, Keith Stewart, Young Trieu, Suzanne Trudel, Christine I. Chen

    Izdano 2013
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

    MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma od Esther Masih‐Khan, Suzanne Trudel, Carla Heise, Zhihua Li, Joshua Paterson, Vincent Nadeem, Ellen Wei, David Roodman, Jaime O. Claudio, P. Leif Bergsagel, A. Keith Stewart

    Izdano 2006
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop

    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop od Aleksandra A. Pandyra, Peter Mullen, Manpreet Kalkat, Rosemary Yu, Janice T. Pong, Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn

    Izdano 2014
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

    A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma od Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules

    Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules od Steven Fletcher, Brent D. G. Page, Xiaolei Zhang, Peibin Yue, Zhihua Li, Sumaiya Sharmeen, Jagdeep Singh, Wei Zhao, Aaron D. Schimmer, Suzanne Trudel, James Turkson, Patrick T. Gunning

    Izdano 2011
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain

    Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain od Brent D. G. Page, Steven Fletcher, Peibin Yue, Zhihua Li, Xiaolei Zhang, Sumaiya Sharmeen, Alessandro Datti, Jeffrey L. Wrana, Suzanne Trudel, Aaron D. Schimmer, James Turkson, Patrick T. Gunning

    Izdano 2011
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

    Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial od Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece

    Izdano 2024
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

    Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study od Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Axel Hoos, Ira Gupta, Véronique Bragulat, Zangdong He, Joanna Opalinska, Adam D. Cohen

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

    Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Synd... od Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodríguez‐Otero, Simon J. Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Fenimore Cooper, María‐Victoria Mateos

    Izdano 2022
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: